Breaking News, Collaborations & Alliances

Regulus Earns Biogen Milestone

Advances MS Research

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regulus Therapeutics Inc. has earned a milestone payment from Biogen Idec under the companies’ research collaboration to identify microRNAs as biomarkers for multiple sclerosis (MS). Regulus’ microMarkers division used its technology platform to meet quality specifications for extracting and reproducibly profiling microRNAs from an initial set of whole blood samples of a recent Biogen MS therapy trial. Regulus’ microMarkers division is now working to identify a microRNA biomarker sig...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters